fbpx
Pharmacy & Acute Care University
Pharmacy & Acute Care University
Back to Course

Neurology 111

0% Complete
0/0 Steps
  1. Hemorrhagic Stroke
    9 Topics
    |
    2 Quizzes
  2. Status Epilepticus
    10 Topics
    |
    2 Quizzes
  3. Myasthenia Gravis Exacerbation
    9 Topics
    |
    2 Quizzes
  4. Parkinson's Disease
    11 Topics
    |
    2 Quizzes
  5. Traumatic brain injury
    9 Topics
    |
    2 Quizzes
  6. Epilepsy
    9 Topics
    |
    2 Quizzes

Participants 396

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Neurology 111 Parkinson’s Disease Summary
Lesson 4, Topic 11
In Progress

Summary

Lesson Progress
0% Complete

In the context of Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to hallmark motor symptoms such as bradykinesia, tremor, rigidity, and postural instability. Non-motor symptoms are also significant, often preceding motor signs and increasing in complexity as PD advances. Pharmacists play a pivotal role in PD management, optimizing pharmacotherapy, educating patients, and monitoring outcomes. Pharmacologic treatment is symptomatic, with levodopa being the cornerstone, supplemented by dopamine agonists, MAO-B inhibitors, and other agents as the disease progresses. Non-pharmacological interventions such as physical, occupational, and speech therapies are integral for maintaining quality of life. New research into the genetic underpinnings of PD holds promise for future targeted therapies, but currently, a cure remains out of reach. Clinicians must be adept at diagnosing PD, differentiating it from other parkinsonian syndromes, and managing the complex interplay of motor and non-motor symptoms with a personalized approach to care.

References

  1. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early‑onset Parkinsonism. Lancet Neurol. 2006;5:355‑63.
  2. Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, et al. Parkinson’s disease and Parkinsonism in a longitudinal study: Two‑fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 2000;55:1358‑63.
  3. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, et al. Incidence of Parkinson’s disease: Variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157:1015‑22​​.
  4. Willis AW, Roberts E, Beck JC, Fiske B, Ross W, Savica R, Van Den Eeden SK, Tanner CM, Marras C; Parkinson’s Foundation P4 Group. Incidence of Parkinson disease in North America. NPJ Parkinsons Dis. 2022 Dec 15;8(1):170. doi: 10.1038/s41531-022-00410-y. PMID: 36522332; PMCID: PMC9755252.
  5. Koch, J. M., Dashtipour, K., & Chen, J. J. (2023). Parkinson Disease. In DiPiro’s Pharmacotherapy: A Pathophysiologic Approach (12th ed., Chapter 78)​
  6. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol 2021; 20:385.
  7. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30:1591.
  8. Findley LJ, Gresty MA, Halmagyi GM. Tremor, the cogwheel phenomenon and clonus in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1981; 44:534.
  9. Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 67:646.
  10. Louis ED, Levy G, Côte LJ, et al. Clinical correlates of action tremor in Parkinson disease. Arch Neurol 2001; 58:1630.
  11. Jain S, Lo SE, Louis ED. Common misdiagnosis of a common neurological disorder: how are we misdiagnosing essential tremor? Arch Neurol 2006; 63:1100.
  12. Radhakrishnan, K., & Goyal, V. (2018). Parkinson’s Disease: A Review. Neurology India, 66(Supplement 1), S26-S35. Link to the article.
  13. Tysnes, O. B., & Storstein, A. (2017). Epidemiology of Parkinson’s disease. Journal of Neural Transmission, 124(8), 901-905. Link to the article.
  14. Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017). Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 18(8), 509. Link to the article.
  15. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591-1601. doi: 10.1002/mds.26424.
  16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
  17. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord. 2003;18 Suppl 7:S43-51. doi: 10.1002/mds.10557.
  18. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2018; 33:1248.
  19. Pringsheim T, Day GS, Smith DB, et al. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology 2021; 97:942.
  20. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311:1670.
  21. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001; 56:S1.
  22. Rogers G, Davies D, Pink J, Cooper P. Parkinson’s disease: summary of updated NICE guidance. BMJ 2017; 358:j1951.
  23. Fahn S, Bressman SB. Should levodopa therapy for Parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984; 11:200.
  24. Muzerengi S, Clarke CE. Initial drug treatment in Parkinson’s disease. BMJ 2015; 351:h4669.
  25. Horn S, Stern MB. The comparative effects of medical therapies for Parkinson’s disease. Neurology 2004; 63:S7.
  26. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009;72(suppl 4):S1-136.Extensive treatise on the pathophysiology and treatment of Parkinson disease.